Francois Cedric's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Dec 21, 2022
- Accession no.
- 0001127602-22-028072
- Filed
- Dec 21, 2022
- Trade date
- Apr 25-Dec 19, 2022
- Filing delay
- 240 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.47M. It was filed 240 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Francois CedricCIK 0001658080 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 25, 2022 | Common Stock | JOtherDisposed | −12,500 | $0.00 | $0 | 943,440 | Direct | |
| Dec 19, 2022 | Common Stock | MOption exerciseAcquired | +28,200 | $2.67 | +$75,294 | 971,640 | Direct | |
| Dec 19, 2022 | Common Stock | MOption exerciseAcquired | +15,000 | $3.76 | +$56,400 | 986,640 | Direct | |
| Dec 19, 2022 | Common Stock | MOption exerciseAcquired | +6,688 | $14.95 | +$99,985.6 | 993,328 | Direct | |
| Dec 19, 2022 | Common Stock | SSaleDisposed | −3,751 | $51.97F3 | −$194,939.47 | 989,577 | Direct | |
| Dec 19, 2022 | Common Stock | SSaleDisposed | −24,449 | $52.07F4 | −$1,273,059.43 | 965,128 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2022 | Common Stock | MOption exerciseDisposed | −28,200 | $0.00 | $0 | 450,000 | Direct | |
| Dec 19, 2022 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 258,840 | Direct | |
| Dec 19, 2022 | Common Stock | MOption exerciseDisposed | −6,688 | $0.00 | $0 | 273,312 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Sale price within range of $1. Min. $50.695 - Max. $51.680
Referenced by the price of 1 transaction in Table I.
- F4
Sale price within range of $1. Min. $51.695 - Max. $52.400
Referenced by the price of 1 transaction in Table I.